- Home
- ESGL vs ARMP Comparison
ESGL vs ARMP Comparison
Compare ESGL & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGL
- ARMP
- Stock Information
- Founded
- ESGL 1999
- ARMP N/A
- Country
- ESGL Singapore
- ARMP United States
- Employees
- ESGL N/A
- ARMP N/A
- Industry
- ESGL
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESGL
- ARMP Health Care
- Exchange
- ESGL Nasdaq
- ARMP Nasdaq
- Market Cap
- ESGL 114.6M
- ARMP 92.4M
- IPO Year
- ESGL N/A
- ARMP N/A
- Fundamental
- Price
- ESGL $2.84
- ARMP $2.55
- Analyst Decision
- ESGL
- ARMP Strong Buy
- Analyst Count
- ESGL 0
- ARMP 1
- Target Price
- ESGL N/A
- ARMP $9.00
- AVG Volume (30 Days)
- ESGL 10.9K
- ARMP 9.4K
- Earning Date
- ESGL 09-23-2025
- ARMP 08-12-2025
- Dividend Yield
- ESGL N/A
- ARMP N/A
- EPS Growth
- ESGL N/A
- ARMP N/A
- EPS
- ESGL N/A
- ARMP N/A
- Revenue
- ESGL $6,099,784.00
- ARMP $6,868,000.00
- Revenue This Year
- ESGL N/A
- ARMP $8.43
- Revenue Next Year
- ESGL N/A
- ARMP N/A
- P/E Ratio
- ESGL N/A
- ARMP N/A
- Revenue Growth
- ESGL N/A
- ARMP 84.67
- 52 Week Low
- ESGL $0.90
- ARMP $0.90
- 52 Week High
- ESGL $3.87
- ARMP $2.96
- Technical
- Relative Strength Index (RSI)
- ESGL 54.15
- ARMP 53.44
- Support Level
- ESGL $2.49
- ARMP $2.44
- Resistance Level
- ESGL $2.70
- ARMP $2.65
- Average True Range (ATR)
- ESGL 0.15
- ARMP 0.16
- MACD
- ESGL 0.01
- ARMP -0.01
- Stochastic Oscillator
- ESGL 100.00
- ARMP 48.48
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.